Bladder Cancer

Latest News

Cretostimogene grenadenorepvec made available through expanded access program
Cretostimogene grenadenorepvec made available through expanded access program

June 18th 2024

Cretostimogene grenadenorepvec is an intravesical oncolytic immunotherapy currently under investigation in the phase 3 trials.

UGN-102 demonstrates long-term durability in NMIBC
UGN-102 demonstrates long-term durability in NMIBC

June 13th 2024

Cretostimogene Grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC
Cretostimogene Grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC

June 5th 2024

Sacituzumab govitecan falls short in phase 3 trial for metastatic urothelial carcinoma
Sacituzumab govitecan falls short in phase 3 trial for metastatic urothelial carcinoma

May 31st 2024

Nivolumab plus chemotherapy approved in EU for urothelial carcinoma
Nivolumab plus chemotherapy approved in EU for urothelial carcinoma

May 29th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.